Primary Analysis of a Prospective, Randomized, Single-Blinded Phase II Trial Evaluating the HER2 Peptide AE37 Vaccine in Breast Cancer Patients to Prevent Recurrence

This phase II trial of the AE37 vaccine shows no benefit in the intention to treat population. However, the trial confirms the vaccine to be safe and capable of stimulating an immune response. Prespecified subgroup analyses show the vaccine may reduce the recurrence rate in triple negative breast cancer patients suggesting an appropriate patient population for further clinical investigation.

from Cancer via ola Kala on Inoreader http://ift.tt/1Szj2b9
via IFTTT